» Articles » PMID: 33526590

Deficits in the Skeletal Muscle Transcriptome and Mitochondrial Coupling in Progressive Diabetes-Induced CKD Relate to Functional Decline

Overview
Journal Diabetes
Specialty Endocrinology
Date 2021 Feb 2
PMID 33526590
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Two-thirds of people with type 2 diabetes mellitus (T2DM) have or will develop chronic kidney disease (CKD), which is characterized by rapid renal decline that, together with superimposed T2DM-related metabolic sequelae, synergistically promotes early frailty and mobility deficits that increase the risk of mortality. Distinguishing the mechanisms linking renal decline to mobility deficits in CKD progression and/or increasing severity in T2DM is instrumental both in identifying those at high risk for functional decline and in formulating effective treatment strategies to prevent renal failure. While evidence suggests that skeletal muscle energetics may relate to the development of these comorbidities in advanced CKD, this has never been assessed across the spectrum of CKD progression, especially in T2DM-induced CKD. Here, using next-generation sequencing, we first report significant downregulation in transcriptional networks governing oxidative phosphorylation, coupled electron transport, electron transport chain (ETC) complex assembly, and mitochondrial organization in both middle- and late-stage CKD in T2DM. Furthermore, muscle mitochondrial coupling is impaired as early as stage 3 CKD, with additional deficits in ETC respiration, enzymatic activity, and increased redox leak. Moreover, mitochondrial ETC function and coupling strongly relate to muscle performance and physical function. Our results indicate that T2DM-induced CKD progression impairs physical function, with implications for altered metabolic transcriptional networks and mitochondrial functional deficits as primary mechanistic factors early in CKD progression in T2DM.

Citing Articles

Novel coenzyme Q6 genetic variant increases susceptibility to pneumococcal disease.

Walker E, Javati S, Todd E, Matlam J, Lin X, Bryant M Nat Immunol. 2024; 25(12):2247-2258.

PMID: 39496954 PMC: 11908386. DOI: 10.1038/s41590-024-01998-4.


Measurement of Mitochondrial Respiration in Human and Mouse Skeletal Muscle Fibers by High-Resolution Respirometry.

Pietka T, Brookheart R J Vis Exp. 2024; (212).

PMID: 39431793 PMC: 11803922. DOI: 10.3791/66834.


A tryptophan-derived uremic metabolite/Ahr/Pdk4 axis governs skeletal muscle mitochondrial energetics in chronic kidney disease.

Thome T, Vugman N, Stone L, Wimberly K, Scali S, Ryan T JCI Insight. 2024; 9(10).

PMID: 38652558 PMC: 11141944. DOI: 10.1172/jci.insight.178372.


MANF stimulates autophagy and restores mitochondrial homeostasis to treat autosomal dominant tubulointerstitial kidney disease in mice.

Kim Y, Li C, Gu C, Fang Y, Tycksen E, Puri A Nat Commun. 2023; 14(1):6493.

PMID: 37838725 PMC: 10576802. DOI: 10.1038/s41467-023-42154-0.


Relationship between physical performance and mild cognitive impairment in elderly hemodialysis patients is modified by the presence of diabetes: A multicenter cross-sectional study.

Zhao Y, Song P, Zhu C, Zhang L, Chen X, Zhang H Front Endocrinol (Lausanne). 2022; 13:897728.

PMID: 36157461 PMC: 9501887. DOI: 10.3389/fendo.2022.897728.


References
1.
Greggio C, Jha P, Kulkarni S, Lagarrigue S, Broskey N, Boutant M . Enhanced Respiratory Chain Supercomplex Formation in Response to Exercise in Human Skeletal Muscle. Cell Metab. 2016; 25(2):301-311. DOI: 10.1016/j.cmet.2016.11.004. View

2.
Bittel D, Bittel A, Tuttle L, Hastings M, Commean P, Mueller M . Adipose tissue content, muscle performance and physical function in obese adults with type 2 diabetes mellitus and peripheral neuropathy. J Diabetes Complications. 2014; 29(2):250-7. PMC: 4333054. DOI: 10.1016/j.jdiacomp.2014.11.003. View

3.
Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V . Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012; 7(3):401-8. DOI: 10.2215/CJN.07650711. View

4.
Kestenbaum B, Gamboa J, Liu S, Ali A, Shankland E, Jue T . Impaired skeletal muscle mitochondrial bioenergetics and physical performance in chronic kidney disease. JCI Insight. 2020; 5(5). PMC: 7141399. DOI: 10.1172/jci.insight.133289. View

5.
Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T . Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. J Cachexia Sarcopenia Muscle. 2017; 8(5):735-747. PMC: 5659061. DOI: 10.1002/jcsm.12202. View